The present invention provides novel compounds of Formula (I'), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma)), inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as an interleukin-1 receptor-associated kinase (IRAK) (e.g., IRAKI and/or IRAK4) in the subject.
本发明提供了式(I')的新化合物,以及药学上可接受的盐、溶剂合物、
水合物、多型体、共晶体、互变异构体、立体异构体、同位素标记衍
生物、前药和其组合物。还提供了涉及这些创新化合物或组合物的方法和试剂盒,用于治疗和/或预防患者的增殖性疾病(例如,癌症(例如,白血病、淋巴瘤)、炎症性疾病、自身炎症性疾病和自身免疫性疾病)。使用本发明的化合物或组合物治疗患有增殖性疾病的患者可能会抑制患者体内激酶的异常活性,例如白细胞介素-1受体相关激酶(IRAK)(例如,IRAK1和/或IRAK4)。